EYES Up!
When I tried to look up why shares of Second Sight Medical Products Inc. (EYES) skyrocketed from $1.43 on March 4 to $26 Pre-Market on March 9, all I found was technical trend information, which wrote this off as a surprisingly good catalyst play. There were a couple articles explaining the Argus 2s Retinal Prosthesis System, which earned FDA approval on March 5 and fueled the stock trend. But what I read seemed to focus on tidbits of information relating to this technology, which can be somewhat misleading when removed from the bigger picture. Today, some analysts started suggesting that this is just another meme stock.
